PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. / Munir Ahmad, Shamaila; Martinenaite, Evelina; Hansen, Morten; Junker, Niels; Borch, Troels Holz; Met, Özcan; Donia, Marco; Svane, Inge Marie; Andersen, Mads Hald.
In: OncoImmunology, Vol. 5, No. 8, e1202391, 02.08.2016.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
AU - Munir Ahmad, Shamaila
AU - Martinenaite, Evelina
AU - Hansen, Morten
AU - Junker, Niels
AU - Borch, Troels Holz
AU - Met, Özcan
AU - Donia, Marco
AU - Svane, Inge Marie
AU - Andersen, Mads Hald
PY - 2016/8/2
Y1 - 2016/8/2
N2 - We recently described naturally occurring PD-L1-specific T cells that recognize PD-L1-expressing immune cells as well as malignant cells. In the present study, we investigated whether the immunogenicity of a dendritic cell (DC)-based vaccine could be influenced by co-stimulation with a known PD-L1-derived epitope. We incubated a PD-L1-derived peptide epitope (19 amino acids long) or a control peptide (an irrelevant HIV epitope) with peripheral blood mononuclear cells from patients with malignant melanoma who had received a DC-based vaccine. We observed a significantly higher number of T cells that reacted to the vaccine in cultures that had been co-stimulated with the PD-L1 peptide epitope compared to cultures incubated with control peptide. Next, we characterized a novel PD-L1-derived epitope (23 amino acids long) and found that co-stimulation with both PD-L1 epitopes boosted the immune response elicited by the DC vaccine even further. Consequently, we observed a significant increase in the number of vaccine-reacting T cells in vitro. In conclusion, activation of PD-L1-specific T cells may directly modulate immunogenicity of DC vaccines. Addition of PD-L1 epitopes may thus be an easily applicable and attractive option to augment the effectiveness of cancer vaccines and other immunotherapeutic agents.
AB - We recently described naturally occurring PD-L1-specific T cells that recognize PD-L1-expressing immune cells as well as malignant cells. In the present study, we investigated whether the immunogenicity of a dendritic cell (DC)-based vaccine could be influenced by co-stimulation with a known PD-L1-derived epitope. We incubated a PD-L1-derived peptide epitope (19 amino acids long) or a control peptide (an irrelevant HIV epitope) with peripheral blood mononuclear cells from patients with malignant melanoma who had received a DC-based vaccine. We observed a significantly higher number of T cells that reacted to the vaccine in cultures that had been co-stimulated with the PD-L1 peptide epitope compared to cultures incubated with control peptide. Next, we characterized a novel PD-L1-derived epitope (23 amino acids long) and found that co-stimulation with both PD-L1 epitopes boosted the immune response elicited by the DC vaccine even further. Consequently, we observed a significant increase in the number of vaccine-reacting T cells in vitro. In conclusion, activation of PD-L1-specific T cells may directly modulate immunogenicity of DC vaccines. Addition of PD-L1 epitopes may thus be an easily applicable and attractive option to augment the effectiveness of cancer vaccines and other immunotherapeutic agents.
KW - Anti-tregs
KW - antigen
KW - B7-H1
KW - CD274
KW - co-stimulation
KW - dendritic cell-based vaccine
KW - melanoma
KW - PD-L1
KW - T cells
U2 - 10.1080/2162402X.2016.1202391
DO - 10.1080/2162402X.2016.1202391
M3 - Journal article
C2 - 27622072
AN - SCOPUS:84981489471
VL - 5
JO - OncoImmunology
JF - OncoImmunology
SN - 2162-4011
IS - 8
M1 - e1202391
ER -
ID: 168929777